1. New Conjugates of Hyaluronic Acid with γ-Cyclodextrin as Sorafenib Carrier in Cancer Cells.
- Author
-
Bognanni N, Viale M, Sabatino G, Pappalardo G, and Vecchio G
- Subjects
- Humans, Cell Line, Tumor, Drug Screening Assays, Antitumor, Dose-Response Relationship, Drug, Nanoparticles chemistry, Structure-Activity Relationship, Molecular Structure, Hyaluronic Acid chemistry, Hyaluronic Acid pharmacology, Hyaluronic Acid chemical synthesis, Sorafenib pharmacology, Sorafenib chemistry, gamma-Cyclodextrins chemistry, gamma-Cyclodextrins pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Antineoplastic Agents chemical synthesis, Cell Proliferation drug effects, Drug Carriers chemistry, Drug Carriers chemical synthesis
- Abstract
In recent years, nanoparticles based on cyclodextrins have been widely investigated, mainly for drug delivery. In this work, we synthesized nanoparticles with a hyaluronic acid backbone (11 kDa and 45 kDa) functionalized with γ-cyclodextrins. We tested sorafenib in the presence of the new hyaluronan-cyclodextrin conjugates in A2780 (ovarian cancer), SK-HeP-1 (adenocarcinoma) and MDA-MB-453 (breast cancer) cell lines. We found that hyaluronan-cyclodextrin conjugates improve the antiproliferative activity of sorafenib. Remarkably, the system based on the 11 kDa hyaluronan conjugate was the most effective and, in the MDA-MB-453 cell line, significantly reduced the IC
50 value of sorafenib cells by about 75 %., (© 2024 Wiley-VCH GmbH.)- Published
- 2024
- Full Text
- View/download PDF